Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON).

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subjcutaneously (SC) in adults with symptomatic COPD and a history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Potential participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA) in stable doses throughout at least 3 months prior to enrolment.

A Multi-center, Randomized, 36-month, Parallelgroup, Non-inferiority, Phase III Study to Compare the Effectiveness of 500 mcg QD or alternate regimen of RofLumilast (Daliresp) Therapy Versus 250 mg QD, 500 mg QD three times per week or alternate regimen of Azithromycin Therapy to preveNt COPD Exacerbations (RELIANCE)

This study will test whether daily use of azithromycin will reduce the rate of exacerbations and improve lung ventilation and perfusion assessed by XE-MRI. The sensitivity of XE-MRI to detect COPD progression will be compared with standard clinical assessment measures including standard lung function testing, 6 minute walk testing, and patient reported qualify of life.